Oncology medical affairs advisory
Senior-led support for biotech, pharmaceutical and medtech teams navigating the space between clinical evidence, medical strategy and execution.
From scientific signal to an executable medical plan.
Capabilities
Focused advisory and hands-on delivery—designed to add senior capacity exactly where an internal team needs it.
Translate the asset narrative, treatment landscape and stakeholder needs into a focused medical plan with clear priorities, decisions and measures.
Identify the evidence needed to answer clinically relevant questions and connect interventional, real-world and scientific-communication plans.
Build a practical medical readiness plan that aligns field insight, scientific exchange, content, training and cross-functional dependencies.
Structure high-value scientific engagement—from stakeholder mapping and objective setting through facilitation and actionable insight synthesis.
Turn complex evidence into clear, balanced and audience-relevant scientific narratives, materials and capability-building programs.
Provide structured project leadership with clear decision rights, timelines, risk control and compliant scientific execution.
Working model
Every engagement begins with the decision your team needs to make—not a predefined deliverable. The work then moves through four disciplined stages.
Scope an engagementDefine the decision, stakeholders, evidence base, constraints and success criteria.
Test assumptions against data, field intelligence and the clinical context.
Create shared priorities, roles and a realistic path across functions.
Execute the work, capture learning and leave the team with usable tools.
Selected impact
Anonymized examples from oncology, medical technology and cross-functional medical affairs work.
Supported medical launch readiness across a West German oncology territory, translating stakeholder needs into focused scientific activity and cross-functional action.
Planned and delivered four advisory boards, aligning objectives and content, coordinating expert engagement and synthesizing recommendations for internal teams.
Evaluated interventional and real-world evidence for oncology-focused medical technology, translating findings into recommendations for medical, clinical, regulatory and business stakeholders.
*Contextual business result following launch; no claim of sole or direct causation is implied.
Expertise base
The consultancy is grounded in 15+ years of international experience across pharmaceutical, medical-device, biotechnology and academic oncology environments—including more than seven post-PhD years.
That breadth creates a practical bridge between translational science, clinical development, field medical insight and the realities of launch and lifecycle execution.
Flexible engagement
Embedded senior support for an evolving portfolio, launch or capability build.
Ownership of a strategy, evidence, engagement or communications deliverable.
Fast, decision-oriented analysis and alignment for a time-critical question.
Start a conversation
Share the asset stage, the decision in front of your team and the support you need. Initial conversations are confidential and without obligation.